RNA241115P55000
- 9.70
- 0.000.00%
Avidity Biosciences Newsroom
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $78
Express News | Avidity Biosciences Inc : TD Cowen Raises Target Price to $78 From $56
S&P 500 Futures Rise In Premarket Trading; JB Hunt Transport, Trump Media & Tech Lead
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
Capitulation in Biotech Is Near, as Well as a Rally – Piper Sandler
Avidity Biosciences Insider Sold Shares Worth $1,349,259, According to a Recent SEC Filing
12 Health Care Stocks Moving In Monday's After-Market Session
Why Avidity Biosciences Zoomed to a 12% Gain This Week
Capricor Stock Rallies 20% on DMD Data Presentation Update
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $56
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $56 to $75
Analysts' Top Healthcare Picks: DocGo (DCGO), Avidity Biosciences (RNA)
Analysts Conflicted on These Healthcare Names: LivaNova (LIVN), Johnson & Johnson (JNJ) and Avidity Biosciences (RNA)
Sector Update: Health Care Stocks Steady Premarket Thursday
Avidity Biosciences: FDA Removes Partial Clinical Hold On Del-desiran - Quick Facts
Express News | Avidity Biosciences Inc - Del-Desiran Receives Multiple FDA and EMA Designations
Express News | Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (Del-Desiran/Aoc 1001)
Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024?
Avidity Biosciences to Participate in Upcoming Investor Conference
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases